NCT05802407Recruiting
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 12 Apr 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 27 Mar 2023
- Start date
- 1 Feb 2023
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT05802407
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 Feb 2023 to the primary completion date, 1 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- treated with any systemic antitumor treatment before first-line chemotherapy onset;
Other illness
- a known diagnosis of pancreatic cancer other than ductal adenocarcinoma;
Other
- died or lost to follow-up within one month after the initiation of adjuvant chemotherpay;
- combined with other primary malignances.
Who the study is looking for
- patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection);
- both sexes, age ≥18 years old;
- ECOG performance status score ≤2;
- the expected survival time was ≥3 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.